BUZZ-Australia's Neuren soars as partner Acadia wins FDA nod for Rett syndrome treatment** Shares of Neuren Pharmaceuticals NEU.AX soar as much as 3.8% to A$19.73, post their biggest intraday pct gain since Dec 5** Co says partner Acadia Pharmaceuticals ACAD.O received U.S. FDA approval for DAYBUE STIX (trofinetide) for oral solution** DAYBUE STIX is a powder formulation for treatment of Rett syndrome, a rare genetic disorder that affects brain development** Co receives royalties on net sales** YTD, shares up 57.6%
(Reporting by Nichiket Sunil in Bengaluru)
((Nichiket.Sunil@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments